Skip to main content
Premium Trial:

Request an Annual Quote

Progenika Licenses Protein Array Tech from Harvard Spin-out Auguron

NEW YORK (GenomeWeb News) –Harvard University spin-out company Auguron Biosciences has licensed its Nucleic Acid Programmable Protein Array (NAPPA) technology to Proteomika, a subsidiary of Progenika Biopharma.
 
Under the agreement, Proteomika may use the NAPPA technology at its facilities for in its autoimmune research and service programs, and it may exercise an option to negotiate an exclusive license to NAPPA within the field of biomarker discovery for inflammatory bowel disease and lupus.
 
Proteomika CEO Laureano Simon said that lupus and IBD sufferers “need better biomarkers for diagnosis, prognosis, and drug response,” and that the NAPPA technology will provide it with multiplex technology to discover antibodies that can be applied to both diseases.
 
Auguron was started in early 2007 as a commercialization arm for the Harvard Institute for Proteomics.
 
Financial terms of the agreement were not released.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.